Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?

Abstract Therapy for the inflammatory bowel diseases increasingly includes the use of immune‐modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T‐cell lymphoma (HSTCL)—a rare and all but incurable form of non‐Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

[1]  Mark Avigan,et al.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. , 2007, Journal of pediatric gastroenterology and nutrition.

[2]  J. Rosh,et al.  Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned. , 2007, Journal of pediatric gastroenterology and nutrition.

[3]  L. Biancone,et al.  Treatment with biologic therapies and the risk of cancer in patients with IBD , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[4]  J. Hyams.  Biological Therapy in Ulcerative Colitis , 2006 .

[5]  A. Griffiths,et al.  PATTERNS OF INFLIXIMAB USE IN CHILDREN WITH CROHN DISEASE , 2006 .

[6]  D. Culligan,et al.  A case of hepatosplenic γ–δ T‐cell lymphoma with a transient response to Fludarabine and Alemtuzumab , 2006, European journal of haematology.

[7]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[8]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[9]  Y. Volkov,et al.  The hepatitis C envelope 2 protein inhibits LFA-1-transduced protein kinase C signaling for T-lymphocyte migration. , 2006, Gastroenterology.

[10]  J. Kuttesch,et al.  Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature. , 2005, Journal of pediatric hematology/oncology.

[11]  M. Dubinsky,et al.  A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine , 2005, The American Journal of Gastroenterology.

[12]  F. Rizzello,et al.  Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study , 2005, Gut.

[13]  B. Kirschner,et al.  Workshop Report: Prevention of Postoperative Recurrence in Crohn's Disease , 2005, Journal of pediatric gastroenterology and nutrition.

[14]  M. Panzara,et al.  Natalizumab and progressive multifocal leukoencephalopathy. , 2005, The New England journal of medicine.

[15]  C. Brensinger,et al.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.

[16]  M. Björkholm,et al.  Risk of haematopoietic cancer in patients with inflammatory bowel disease , 2005, Gut.

[17]  R. Baldassano,et al.  Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. , 2005, Journal of pediatric gastroenterology and nutrition.

[18]  S. Hanauer,et al.  A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease , 2005 .

[19]  M. Bala,et al.  Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[21]  P. Gaulard,et al.  Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients , 2003 .

[22]  H. Muller-Hermelink,et al.  The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. , 2003, Blood.

[23]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[24]  J. Markowitz,et al.  Consensus and Controversy in the Management of Pediatric Crohn Disease: An International Survey , 2003, Journal of pediatric gastroenterology and nutrition.

[25]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[26]  J. Mate,et al.  Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine , 2003, Leukemia & lymphoma.

[27]  W. Sandborn,et al.  Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. , 2001, Gastroenterology.

[28]  G. Stukenborg,et al.  The Incidence of Lymphoid and Myeloid Malignancies Among Hospitalized Crohn’s Disease Patients , 2001, Inflammatory bowel diseases.

[29]  M. Gulley,et al.  Hepatosplenic αβ T-cell lyrnphomas: A report of 14 cases and comparison with hepatosplenic γδ T-cell lymphomas , 2001 .

[30]  E. Kliewer,et al.  Cancer risk in patients with inflammatory bowel disease , 2001, Cancer.

[31]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[32]  E. Weidmann.  Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990 , 2000, Leukemia.

[33]  G. Lichtenstein,et al.  Cancer risk in patients with inflammatory bowel disease. , 1999, Gastroenterology clinics of North America.

[34]  T. Greiner,et al.  Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. , 1996, Blood.

[35]  J. Downing,et al.  Non-Hodgkin's lymphoma in childhood. , 1996, The New England journal of medicine.

[36]  A. Ahlbom,et al.  Crohn's disease and cancer: a population-based cohort study. , 1994, Gastroenterology.

[37]  H. Adami,et al.  Extracolonic malignancies in inflammatory bowel disease , 1991, Cancer.

[38]  P. Gaulard,et al.  Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. , 1990, The American journal of pathology.

[39]  P. Gaulard,et al.  Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. , 1990, Blood.

[40]  D. Sachar,et al.  Extraintestinal cancers in inflammatory bowel disease , 1985, Cancer.

[41]  A. S. Mcneish,et al.  Long term prognosis of Crohn's disease with onset in childhood and adolescence. , 1984, Gut.

[42]  M. Kamoun,et al.  Erythrophagocytic Tγ Lymphoma , 1981 .

[43]  G. Nahler.  Dear Doctor letter , 2009 .

[44]  S. Hanauer,et al.  A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. , 2005, Alimentary pharmacology & therapeutics.

[45]  P. Gaulard,et al.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. , 2003, Blood.

[46]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[47]  M. Kamoun,et al.  Erythrophagocytic T gamma lymphoma: a clinicopathologic entity resembling malignant histiocytosis. , 1981, The New England journal of medicine.

[48]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.